Letter to the editor: Successful treatment of multidrug‐resistant hepatis C after >12 months of continuous therapy with direct‐acting antivirals
Wenhao Luo, Ying Zhang, Taiping Zhang – 2 August 2022
Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation‐driven hepatocarcinogenesis
Binyong Liang, Haichuan Wang, Yu Qiao, Xue Wang, Manning Qian, Xinhua Song, Yi Zhou, Yi Zhang, Runze Shang, Li Che, Yifa Chen, Zhiyong Huang, Hong Wu, Satdarshan P. Monga, Yong Zeng, Diego F. Calvisi, Xiaoping Chen, Xin Chen – 2 August 2022
Letter to the editor: Cautious interpretation of the compensation of insulin‐mTORC1 activation to promote liver regeneration in the absence of hepatocyte β‐catenin
Cong Ning, Xin‐Mu Zhang, Xin‐Ting Sang, Hai‐Tao Zhao – 1 August 2022
“Long‐term” is getting longer for children receiving liver transplantation grafts
Pamela L. Valentino – 31 July 2022
Waitlist mortality in pediatric liver transplantation: The goal is zero
George V. Mazariegos, Kyle A. Soltys, Emily R. Perito – 31 July 2022
A new approach to manage aberrant hepatic arteries in liver transplantation: Is one better than two?
Quirino Lai, Jan Lerut – 30 July 2022
HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma
Na Sun, Ceng Zhang, Yi‐Te Lee, Benjamin V. Tran, Jing Wang, Hyoyong Kim, Junseok Lee, Ryan Y. Zhang, Jasmine J. Wang, Junhui Hu, Zhicheng Zhang, Manaf S. Alsudaney, Kuan‐Chu Hou, Hubert Tang, Tiffany X. Zhang, Icy Y. Liang, Ziang Zhou, Mengxiang Chen, Angela Hsiao‐Jiun Yeh, Wenyuan Li, Xianghong Jasmine Zhou, Helena R. Chang, Steven‐Huy B. Han, Saeed Sadeghi, Richard S. Finn, Sammy Saab, Ronald W. Busuttil, Mazen Noureddin, Walid S. Ayoub, Alexander Kuo, Vinay Sundaram, Buraq Al‐Ghaieb, Juvelyn Palomique, Kambiz Kosari, Irene K. Kim, Tsuyoshi Todo, Nicholas N.
Improving DCD liver utilization by challenging the status quo
Mark J. Hobeika, Flavio E. Baio, Ashish Saharia – 29 July 2022
Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis
Jasmohan S. Bajaj, K. Rajender Reddy, Puneeta Tandon, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jacqueline G. O'Leary, Florence Wong, Jennifer Lai, Hugo Vargas, Paul J. Thuluvath, Ram M. Subramanian, Marcela Pena‐Rodriguez, Masoumeh Sikaroodi, Leroy R. Thacker, Patrick M. Gillevet – 29 July 2022 – Cirrhosis is complicated by a high rate of nosocomial infections (NIs), which result in poor outcomes and are challenging to predict using clinical variables alone. Our aim was to determine predictors of NI using admission serum metabolomics and gut microbiota in inpatients with cirrhosis.
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient‐reported quality of life
Laura Heath, Paul Aveyard, Jeremy W. Tomlinson, Jeremy F. Cobbold, Dimitrios A. Koutoukidis – 27 July 2022 – Nonalcoholic steatohepatitis (NASH) is a prevalent chronic disease that is associated with a spectrum of liver fibrosis and can lead to cirrhosis. Patients with NASH report lower health‐related quality of life (HRQoL) than the general population. It remains uncertain how changes in histologic severity are associated with changes in HRQoL.